Paul T Heath

Summary

Affiliation: St George's
Country: UK

Publications

  1. ncbi Risk factors for late onset gram-negative infections: a case-control study
    Srabani Samanta
    Division of Child Health, St George s, University of London, Cranmer Terrace, Tooting, London, UK
    Arch Dis Child Fetal Neonatal Ed 96:F15-8. 2011
  2. ncbi Group B streptococcal carriage, serotype distribution and antibiotic susceptibilities in pregnant women at the time of delivery in a refugee population on the Thai-Myanmar border
    Claudia Turner
    Shoklo Malaria Research Unit, Thailand
    BMC Infect Dis 12:34. 2012
  3. ncbi Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial
    Irja Lutsar
    Institute of Microbiology, University of Tartu, Estonia
    Trials 12:215. 2011
  4. ncbi Perinatal group B streptococcal disease
    Paul T Heath
    Vaccine Institute and Division of Child Health, St George s, University of London, London SW17 0RE, UK
    Best Pract Res Clin Obstet Gynaecol 21:411-24. 2007
  5. ncbi Group B streptococcal disease in infants: a case control study
    P T Heath
    Child Health and Vaccine Institute, St George s, University of London, UK
    Arch Dis Child 94:674-80. 2009
  6. ncbi An update on vaccination against group B streptococcus
    Paul T Heath
    Vaccine Institute and Division of Clinical Sciences, St George s, University of London, Cranmer Terrace, London SW17 0RE, UK
    Expert Rev Vaccines 10:685-94. 2011
  7. ncbi The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children
    Ifeanyichukwu O Okike
    Vaccine Institute, St George s, University of London, London, United Kingdom
    Vaccine 29:6636-40. 2011
  8. ncbi Immunisation practices of paediatric oncology and shared care oncology consultants: a United Kingdom survey
    Jessica Bate
    Division of Child Health, St George s University of London, London, UK
    Pediatr Blood Cancer 54:941-6. 2010
  9. ncbi Improving the outcome of neonatal meningitis
    Eva P Galiza
    Vaccine Institute, London, UK
    Curr Opin Infect Dis 22:229-34. 2009
  10. ncbi PEPtalk: postexposure prophylaxis against varicella in children with cancer
    Jessica Bate
    Division of Clinical Sciences, St George s, University of London, London, UK
    Arch Dis Child 96:841-5. 2011

Collaborators

Detail Information

Publications20

  1. ncbi Risk factors for late onset gram-negative infections: a case-control study
    Srabani Samanta
    Division of Child Health, St George s, University of London, Cranmer Terrace, Tooting, London, UK
    Arch Dis Child Fetal Neonatal Ed 96:F15-8. 2011
    ..To determine the incidence, mortality and risk factors for neonatal late onset gram-negative sepsis and meningitis (LOGNS)...
  2. ncbi Group B streptococcal carriage, serotype distribution and antibiotic susceptibilities in pregnant women at the time of delivery in a refugee population on the Thai-Myanmar border
    Claudia Turner
    Shoklo Malaria Research Unit, Thailand
    BMC Infect Dis 12:34. 2012
    ..Maternal carriage of GBS is a prerequisite for the development of early onset GBS neonatal sepsis but there is a paucity of carriage data published from the developing world, in particular South East Asia...
  3. ncbi Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial
    Irja Lutsar
    Institute of Microbiology, University of Tartu, Estonia
    Trials 12:215. 2011
    ..The study will start recruitment in September 2011; the total duration is of 24 months. TRIAL REGISTRATION: EudraCT 2011-001515-31...
  4. ncbi Perinatal group B streptococcal disease
    Paul T Heath
    Vaccine Institute and Division of Child Health, St George s, University of London, London SW17 0RE, UK
    Best Pract Res Clin Obstet Gynaecol 21:411-24. 2007
    ..Decisions on which strategy to use will depend on a number of factors. A swab-based approach appears to have higher efficacy but is likely to lead to more antibiotic exposure...
  5. ncbi Group B streptococcal disease in infants: a case control study
    P T Heath
    Child Health and Vaccine Institute, St George s, University of London, UK
    Arch Dis Child 94:674-80. 2009
    ..To describe and quantify the maternal and neonatal factors associated with Group B streptococcus (GBS) disease in infants <90 days of age...
  6. ncbi An update on vaccination against group B streptococcus
    Paul T Heath
    Vaccine Institute and Division of Clinical Sciences, St George s, University of London, Cranmer Terrace, London SW17 0RE, UK
    Expert Rev Vaccines 10:685-94. 2011
    ..Issues yet to be resolved include the safety and acceptability of vaccination during pregnancy, the durability of vaccine-derived immunity and the regulatory issues required for licensure...
  7. ncbi The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children
    Ifeanyichukwu O Okike
    Vaccine Institute, St George s, University of London, London, United Kingdom
    Vaccine 29:6636-40. 2011
    ..There were no published data available regarding the immunogenicity of this vaccine in such children...
  8. ncbi Immunisation practices of paediatric oncology and shared care oncology consultants: a United Kingdom survey
    Jessica Bate
    Division of Child Health, St George s University of London, London, UK
    Pediatr Blood Cancer 54:941-6. 2010
    ..In March 2002, the Royal College of Paediatrics and Child Health (RCPCH) introduced guidelines for re-immunisation of children after completion of standard-dose chemotherapy and after haematopoietic stem cell transplant (HSCT)...
  9. ncbi Improving the outcome of neonatal meningitis
    Eva P Galiza
    Vaccine Institute, London, UK
    Curr Opin Infect Dis 22:229-34. 2009
    ..This review focuses on recent advances in the management of neonatal meningitis and its implications for improved outcomes...
  10. ncbi PEPtalk: postexposure prophylaxis against varicella in children with cancer
    Jessica Bate
    Division of Clinical Sciences, St George s, University of London, London, UK
    Arch Dis Child 96:841-5. 2011
    ....
  11. ncbi Neonatal infections in England: the NeonIN surveillance network
    Stefania Vergnano
    Division of Child Health, St George s, University of London, Cranmer Terrace, London, UK
    Arch Dis Child Fetal Neonatal Ed 96:F9-F14. 2011
    ..Neonatal infection is an important cause of morbidity and mortality. Neonatal infection surveillance networks are necessary for defining the epidemiology of infections and monitoring changes over time...
  12. ncbi The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009
    Clarissa Oeser
    Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St George s, University of London, London, United Kingdom
    Pediatr Infect Dis J 32:23-6. 2013
    ..This study aimed to describe the epidemiology of pediatric candidemia in England and Wales during a 10-year period as a means of quantifying the changing burden of infection and identifying emerging trends...
  13. ncbi Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom
    Jessica Bate
    Dept of Child Health, St George s, University of London, London, England
    Clin Infect Dis 51:e95-104. 2010
    ..Children with cancer have an increased susceptibility to influenza infection. The objective of this study was to assess the immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer...
  14. ncbi Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom
    Shamez Ladhani
    Academic Unit of Paediatrics, Barts and the London School of Medicine and Dentistry, Centre for Infections, Health Protection Agency, St George s, University of London, London, United Kingdom
    Clin Infect Dis 49:372-80. 2009
    ..The objective of this study was to determine Hib antibody concentrations in children several years after infection and to identify risk factors for low antibody concentrations...
  15. ncbi Strategies for preventing group B streptococcal disease
    Esse Menson
    Pediatric Infectious Diseases Unit, St George's Hospital, London, United Kingdom
    Adv Exp Med Biol 549:231-6. 2004
  16. ncbi Characterization of group B streptococci recovered from infants with invasive disease in England and Wales
    Abbie M Weisner
    Streptococcus and Diphtheria Reference Unit, Respiratory and Systemic Infection Laboratory, Health Protection Agency, Colindale, London, United Kingdom
    Clin Infect Dis 38:1203-8. 2004
    ..A trivalent vaccine containing capsular polysaccharides III, Ia, and V could theoretically provide coverage against 85% of the cases of GBS disease among infants in England and Wales...
  17. ncbi Group B streptococcal disease in UK and Irish infants younger than 90 days
    Paul T Heath
    Vaccine Institute, St George s Hospital, London, UK
    Lancet 363:292-4. 2004
    ..53 infants died (overall 9.7%). We have established the minimum current burden of group B streptococcal disease in UK and Irish infants. This information will assist in the formulation of guidelines for prevention of this disease...
  18. ncbi Changes in antibiotic resistance rates of invasive Haemophilus influenzae isolates in England and Wales over the last 20 years
    Shamez Ladhani
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    J Antimicrob Chemother 62:776-9. 2008
    ..The aim of this study was to determine trends in antibiotic resistance profiles of invasive clinical Haemophilus influenzae isolates over the last 20 years...
  19. ncbi Respiratory distress related to asymptomatic colonization with group B streptococci
    Benjamin J Stenson
    Pediatr Infect Dis J 26:765; author reply 765-6. 2007
  20. ncbi Vaccination against group B streptococcus
    Paul T Heath
    Department of Child Health and Vaccine Institute, St George s Hospital Medical School, London, UK
    Expert Rev Vaccines 4:207-18. 2005
    ..However, unless the regulatory environment is changed specifically to allow the development of a Group B streptococcus vaccine, it is unlikely that one will ever reach the market...